image
Medtronic plc MDT
Healthcare - Medical - Devices - NYSE - IE
Watchlist
$ 89.315
1.92 %
$ 115 B
Market Cap
27.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one MDT stock under the worst case scenario is HIDDEN Compared to the current market price of 89.3 USD, Medtronic plc is HIDDEN

MDT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one MDT stock under the base case scenario is HIDDEN Compared to the current market price of 89.3 USD, Medtronic plc is HIDDEN

MDT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one MDT stock under the best case scenario is HIDDEN Compared to the current market price of 89.3 USD, Medtronic plc is HIDDEN

MDT Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart MDT

image
1M -4%
6M 0%
1Y 9%
3Y -13%
5Y 19%
All
$96.0$96.0$94.0$94.0$92.0$92.0$90.0$90.0$88.0$88.0$86.0$86.0$84.0$84.0$82.0$82.0$80.0$80.0$78.0$78.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
32.4 B REVENUE
3.64%
Growth Rates
1Year 3.64%
3Years 2.43%
5Years 1.16%
7Years 1.23%
10Years 6.65%
5.14 B OPERATING INCOME
-6.22%
Growth Rates
1Year -6.22%
3Years 4.68%
5Years -3.88%
7Years -0.51%
10Years 2.33%
3.68 B NET INCOME
-2.85%
Growth Rates
1Year -2.85%
3Years 0.42%
5Years -4.59%
7Years -1.28%
10Years 1.83%
6.79 B OPERATING CASH FLOW
12.39%
Growth Rates
1Year 12.39%
3Years 2.84%
5Years -0.64%
7Years -0.19%
10Years 3.19%
-2.37 B INVESTING CASH FLOW
32.26%
Growth Rates
1Year 32.26%
3Years 6.19%
5Years -25.04%
7Years -6.02%
10Years 4.09%
-4.45 B FINANCING CASH FLOW
10.28%
Growth Rates
1Year 10.28%
3Years -2.47%
5Years 3.91%
7Years -4.44%
10Years -17.10%
8.29 B REVENUE
-1.32%
Growth Rates
1Year 3.64%
3Years 2.43%
5Years 1.16%
7Years 1.23%
10Years 6.65%
1.65 B OPERATING INCOME
3.20%
Growth Rates
1Year -6.22%
3Years 4.68%
5Years -3.88%
7Years -0.51%
10Years 2.33%
1.31 B NET INCOME
2.50%
Growth Rates
1Year -2.85%
3Years 0.42%
5Years -4.59%
7Years -1.28%
10Years 1.83%
2.57 B OPERATING CASH FLOW
168.48%
Growth Rates
1Year 12.39%
3Years 2.84%
5Years -0.64%
7Years -0.19%
10Years 3.19%
-843 M INVESTING CASH FLOW
-144.35%
Growth Rates
1Year 32.26%
3Years 6.19%
5Years -25.04%
7Years -6.02%
10Years 4.09%
-1.75 B FINANCING CASH FLOW
-228.28%
Growth Rates
1Year 10.28%
3Years -2.47%
5Years 3.91%
7Years -4.44%
10Years -17.10%
Balance Sheet Medtronic plc
image
Current Assets 21.9 B
Cash & Short-Term Investments 8 B
Receivables 6.13 B
Other Current Assets 7.8 B
Non-Current Assets 68 B
Long-Term Investments 1.62 B
PP&E 7.14 B
Other Non-Current Assets 59.3 B
8.90 %6.81 %8.67 %7.94 %65.89 %Total Assets$90.0b
Current Liabilities 10.8 B
Accounts Payable 2.41 B
Short-Term Debt 1.28 B
Other Current Liabilities 7.1 B
Non-Current Liabilities 28.8 B
Long-Term Debt 24.8 B
Other Non-Current Liabilities 4 B
6.09 %3.22 %17.96 %62.62 %10.11 %Total Liabilities$39.6b
EFFICIENCY
Earnings Waterfall Medtronic plc
image
Revenue 32.4 B
Cost Of Revenue 11.2 B
Gross Profit 21.1 B
Operating Expenses 16.1 B
Operating Income 5.14 B
Other Expenses 1.47 B
Net Income 3.68 B
35b35b30b30b25b25b20b20b15b15b10b10b5b5b0032b(11b)21b(16b)5b(1b)4bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.34% GROSS MARGIN
65.34%
Averages
1Year 65.34%
3Years 66.33%
5Years 66.32%
7Years 67.34%
10Years 67.73%
15.89% OPERATING MARGIN
15.89%
Averages
1Year 15.89%
3Years 17.20%
5Years 16.61%
7Years 17.97%
10Years 18.07%
11.36% NET MARGIN
11.36%
Averages
1Year 11.36%
3Years 13.10%
5Years 13.57%
7Years 13.34%
10Years 13.24%
7.32% ROE
7.32%
Averages
1Year 7.32%
3Years 8.07%
5Years 8.13%
7Years 8.00%
10Years 7.59%
4.09% ROA
4.09%
Averages
1Year 4.09%
3Years 4.59%
5Years 4.58%
7Years 4.50%
10Years 4.16%
4.90% ROIC
4.90%
Averages
1Year 4.90%
3Years 5.34%
5Years 5.55%
7Years 5.56%
10Years 5.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Medtronic plc
image
7b7b6b6b5b5b4b4b3b3b2b2b1b1b00201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 3.68 B
Depreciation & Amortization 2.65 B
Capital Expenditures -1.59 B
Stock-Based Compensation 393 M
Change in Working Capital -484 M
Others 718 M
Free Cash Flow 5.2 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Medtronic plc
image
Wall Street analysts predict an average 1-year price target for MDT of $94.9 , with forecasts ranging from a low of $82 to a high of $106 .
MDT Lowest Price Target Wall Street Target
82 USD -8.19%
MDT Average Price Target Wall Street Target
94.9 USD 6.30%
MDT Highest Price Target Wall Street Target
106 USD 18.68%
Price
Max Price Target
Min Price Target
Average Price Target
11011010510510010095959090858580807575May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
0.78% DIVIDEND YIELD
0.7 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.5002.5002.0002.0001.5001.5001.0001.0000.5000.5000.0000.0000.3050.380.430.460.50.540.580.630.680.690.70.380.580.630.680.690.70.380.430.430.460.460.50.540.540.580.630.680.690.70.381.440.431.820.461.950.52.100.542.190.582.320.631.750.681.850.691.950.72.021.380.690.702015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Medtronic plc
image
Sold
0-3 MONTHS
1.91 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.67 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. zacks.com - 2 weeks ago
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue? Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? zacks.com - 2 weeks ago
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product. seekingalpha.com - 2 weeks ago
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions. zacks.com - 2 weeks ago
FDA classifies recall of Medtronic embolization devices as 'most serious' The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients. reuters.com - 2 weeks ago
Dividend Kings Of The Future A list of 9 companies that may reach Dividend King status in the near future. These companies span various sectors and offer investors a wide range of dividend growth rates and yields. A few of these companies have abnormally high payout ratios, which may hinder their ability to achieve Dividend King status. seekingalpha.com - 2 weeks ago
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2 weeks ago
5 Dividend Stocks That Motley Fool Experts Are Watching Right Now In today's uncertain economic landscape, dividend stocks can serve as anchors in your portfolio. We asked Motley Fool investment experts Matt Argersinger and Anthony Schiavone -- leaders of The Motley Fool's Dividend Investor scorecard within Epic -- to share some of their top dividend picks that combine income potential with business durability. fool.com - 2 weeks ago
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space. zacks.com - 3 weeks ago
The Big 3: KO, MDT, LHX Stability is Kenny Polcari's theme when it comes to today's Big 3. He explains why Cola-Cola (KO), Medtronic (MDT) and L3Harris (LHX) are undervalued names with quality. youtube.com - 3 weeks ago
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS. zacks.com - 3 weeks ago
CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay Platform NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- CGS Immersive™, the leader in enterprise learning that is modernizing training and development with AI and XR technologies, today introduced Cicero™, a hyper realistic roleplay application for upskilling workforces. Using AI-powered interactions, Cicero facilitates immersive roleplay using lifelike personas and real-time feedback in scenarios so realistic, it helps trainees to master the unexpected things that happen in real-life interactions with customers and other business contacts. globenewswire.com - 3 weeks ago
8. Profile Summary

Medtronic plc MDT

image
COUNTRY IE
INDUSTRY Medical - Devices
MARKET CAP $ 115 B
Dividend Yield 0.78%
Description Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Contact 20 On Hatch, Dublin, 2 https://www.medtronic.com
IPO Date May 2, 1973
Employees 95000
Officers Dr. Laura Mauri M.D., M.Sc. Senior Vice President and Chief Scientific & Medical Officer Mr. Ryan Weispfenning Vice President & Head of Investor Relations Mr. Sean M. Salmon Executive Vice President & President of Cardiovascular Portfolio Mr. Gregory L. Smith Executive Vice President of Global Operations & Supply Chain Mr. Mark Ploof Senior Vice President of Global Operations and Business Services Mr. Gary Corona Senior Vice President of Corporate Finance Mr. Geoffrey Straub Martha Chairman of the Board & Chief Executive Officer Mr. Brett A. Wall Executive Vice President & President of Neuroscience Portfolio Mr. Thierry Pieton Chief Financial Officer Dr. Kenneth E. Washington Ph.D. Senior Vice President and Chief Technology & Innovation Officer